HomeCompareKHEXF vs JNJ

KHEXF vs JNJ: Dividend Comparison 2026

KHEXF yields 2.69% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $4.8K in total portfolio value· pulled ahead in Year 9
10 years
KHEXF
KHEXF
● Live price
2.69%
Share price
$10.00
Annual div
$0.27
5Y div CAGR
6.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$630.54
Full KHEXF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — KHEXF vs JNJ

📍 JNJ pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKHEXFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KHEXF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KHEXF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KHEXF
Annual income on $10K today (after 15% tax)
$228.49/yr
After 10yr DRIP, annual income (after tax)
$535.96/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,450.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KHEXF + JNJ for your $10,000?

KHEXF: 50%JNJ: 50%
100% JNJ50/50100% KHEXF
Portfolio after 10yr
$27.9K
Annual income
$2,659.97/yr
Blended yield
9.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

KHEXF
No analyst data
Altman Z
12.2
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KHEXF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKHEXFJNJ
Forward yield2.69%2.13%
Annual dividend / share$0.27$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR6.4%28%
Portfolio after 10y$25.4K$30.3K
Annual income after 10y$630.54$4,689.40
Total dividends collected$4.4K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KHEXF vs JNJ ($10,000, DRIP)

YearKHEXF PortfolioKHEXF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,986$286.01$10,592$272.30+$394.00KHEXF
2$12,067$312.45$11,289$357.73+$778.00KHEXF
3$13,253$341.29$12,123$472.89+$1.1KKHEXF
4$14,554$372.73$13,141$629.86+$1.4KKHEXF
5$15,980$407.01$14,408$846.81+$1.6KKHEXF
6$17,543$444.37$16,021$1,151.60+$1.5KKHEXF
7$19,256$485.10$18,122$1,588.22+$1.1KKHEXF
8$21,133$529.48$20,930$2,228.20+$203.00KHEXF
9← crossover$23,190$577.85$24,792$3,191.91$1.6KJNJ
10$25,444$630.54$30,274$4,689.40$4.8KJNJ

KHEXF vs JNJ: Complete Analysis 2026

KHEXFStock

Keikyu Corporation engages in the transportation, real estate, leisure and service, distribution, and other businesses in Japan. It provides railway, taxi, and shared/chartered bus transportation services. The company also engages in the construction, sale, relocation support, and remodeling of detached houses and condominiums; development and sale of commercial, office, rental buildings, and parking lots; and provision of real estate leasing, brokerage, and consulting services. In addition, it operates leisure facilities, such as hot spring, aquariums, yacht harbors, boat racing, and golf courses; provide advertising agency and travel services; and processes and sells marine products and prepared foods. Further, the company is involved in the operation and management of department stores, shopping centers, and convenience and drug stores; leasing of office buildings and research facilities; contracting of civil engineering and construction, electrical, telecommunications, and pipe work; manufacturing, remodeling, painting, cleaning, and repair of transportation equipment, such as trains and automobiles; management of condominium; and provision of building maintenance, cleaning, security business. Additionally, it engages in the living life support, fresh flower, nursery school management, and life and non-life insurance agency businesses; and provision of computer software design, development, sales, and maintenance services, as well as provides station cleaning, bicycle parking lot management, business card creation, futon drying, home delivery reception and witness, data entry, group passenger reception, accounting, personnel, and temporary staffing services. The company was formerly known as Keihin Electric Express Railway Co., Ltd. and changed its name to Keikyu Corporation in October 2010. Keikyu Corporation was founded in 1898 and is headquartered in Yokohama, Japan.

Full KHEXF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this KHEXF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KHEXF vs SCHDKHEXF vs JEPIKHEXF vs OKHEXF vs KOKHEXF vs MAINKHEXF vs ABBVKHEXF vs MRKKHEXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.